2020-2025 Infectious Vaccines Market Key Factors for Growth and Opportunity Illuminated by New Report | GSK, CSL, J&J, Pfizer, Bavarian Nordic, Novartis AG, Merck, Sanofi Pasteur

Global Infectious Vaccines Market Synopsis:

The exclusive research report on the Global Infectious Vaccines Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Infectious Vaccines Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

Some of the most important key factors driving the growth of the Global Infectious Vaccines Market are increasing consumer awareness regarding health coupled with rising disposable income, growing government activities to control epidemic diseases, rising awareness regarding harmful effects, symptoms, and causes coupled with easy accessibility of drugs, increasing investment by pharmaceutical companies in Research & Development endeavors, growing number of hospitals and healthcare institutions.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273385 .

Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation (Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion. The Infectious Vaccines Market is segmented based on Product, source, application and Regions. On the basis of product, the market is sub-segmented.

In terms of the regional analysis, North America and Europe are expected to account for highest market share over the next few years owing to the presence of numerous pharmaceutical companies dedicated to producing various Infectious Vaccines. APAC is anticipated to witness the fastest growth by 2022 owing to rising epidemic diseases, increasing the number of pharmaceutical industry players and growing disposable income. India, China, and Australia are expected to see the significant market share in the region primarily due to rising immunization initiatives by WHO and growing government action in producing infectious vaccines for diseases such as polio, smallpox, and rotavirus at low cost.

Top Major Key Players in the Global Infectious Vaccines Market:

1 CSL Limited

2 Bavarian Nordic

3 GlaxoSmithKline

4 Emergent Bio Solutions

5 MedImmune

6 Johnson and Johnson

7 Novartis AG

8 Merck

9 Sanofi Pasteur

10 Pfizer and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Infectious Vaccines Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273385/single .

Product Type Segmentation

1 Preventive vaccine

2 Therapeutic vaccine

Industry Segmentation

1 Adults

2 Pediatrics

Global Medical Industry News:

Pfizer (July 13, 2020) - Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2 - Pfizer Inc and BioNTech SE today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.

Fast Track is a process designed to facilitate the development, and expedite the review, of new drugs and vaccines that are intended to treat or prevent serious conditions that have the potential to address an unmet medical need.i This designation was granted based on preliminary data from Phase 1/2 studies that are currently ongoing in the United States and Germany as well as animal immunogenicity studies. The companies released early data from the ongoing U.S. Phase 1/2 study for the product candidate BNT162b1 on July 1, 2020. The manuscript is available on the online preprint server medRxiv and is concurrently undergoing scientific peer-review for potential publication. Early data from the German trial of BNT162b1 are expected to be released in July.

The BNT162 program is evaluating at least four experimental vaccines, each of which represent a unique combination of messenger RNA (mRNA) format and target antigen. BNT162b1 and BNT162b2 are both nucleoside modified RNAs, formulated in lipid nanoparticles. BNT162b1 encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen, while BNT162b2 encodes an optimized SARS-CoV-2 full-length spike protein antigen.

“The FDA’s decision to grant these two COVID-19 vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2,” said Peter Honig, Senior Vice President, Global Regulatory Affairs, Pfizer. “We look forward to continue working closely with the FDA throughout the clinical development of this program, Project Lightspeed, to evaluate the safety and efficacy of these vaccine candidates.”

“We are pleased to have received Fast Track designation from the FDA for two of our vaccine candidates and look forward to working closely with the FDA, along with our partner Pfizer, to expedite the clinical development path forward,” said Özlem Türeci, Chief Medical Officerat BioNTech.

The Project Lightspeed vaccine development program is based on BioNTech’s proprietary mRNA-based technology platforms and supported by Pfizer’s global vaccine development capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world. Pfizer and BioNTech are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all decision-making of both companies. Subject to regulatory approval, the companies are expecting to start a Phase 2b/3 trial as soon as later this month and are anticipating enrolling up to 30,000 subjects. If the ongoing studies are successful, and the vaccine candidate receives regulatory approval, the companies currently expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273385 .

Major Points in Table of Contents:

Global Infectious Vaccines Market Report 2020

1 Infectious Vaccines Product Definition

2 Global Infectious Vaccines Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Infectious Vaccines Shipments

2.2 Global Manufacturer Infectious Vaccines Business Revenue

2.3 Global Infectious Vaccines Market Overview

2.4 COVID-19 Impact on Infectious Vaccines Industry

3 Manufacturer Infectious Vaccines Business Introduction

3.1 CSL Limited (Australia) Infectious Vaccines Business Introduction

3.2 Bavarian Nordic (Denmark) Infectious Vaccines Business Introduction

3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Business Introduction

3.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Business Introduction

3.5 MedImmune LLC (U.S.) Infectious Vaccines Business Introduction

3.6 Johnson and Johnson (U.S.) Infectious Vaccines Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.